Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
FLKS's Cash-to-Debt is ranked higher than
68% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. FLKS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
FLKS' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Equity-to-Asset 0.94
FLKS's Equity-to-Asset is ranked higher than
92% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. FLKS: 0.94 )
Ranked among companies with meaningful Equity-to-Asset only.
FLKS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.94  Med: 0.94 Max: 0.96
Current: 0.94
0.94
0.96
Interest Coverage No Debt
FLKS's Interest Coverage is ranked higher than
59% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. FLKS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
FLKS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 8.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -3073.05
FLKS's Operating Margin % is ranked lower than
86% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. FLKS: -3073.05 )
Ranked among companies with meaningful Operating Margin % only.
FLKS' s Operating Margin % Range Over the Past 10 Years
Min: -3945.2  Med: -3945.2 Max: -3073.05
Current: -3073.05
-3945.2
-3073.05
Net Margin % -3043.70
FLKS's Net Margin % is ranked lower than
87% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. FLKS: -3043.70 )
Ranked among companies with meaningful Net Margin % only.
FLKS' s Net Margin % Range Over the Past 10 Years
Min: -3906.33  Med: -3906.33 Max: -3043.7
Current: -3043.7
-3906.33
-3043.7
ROE % -56.70
FLKS's ROE % is ranked lower than
61% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. FLKS: -56.70 )
Ranked among companies with meaningful ROE % only.
FLKS' s ROE % Range Over the Past 10 Years
Min: -68.05  Med: -60.09 Max: -52.13
Current: -56.7
-68.05
-52.13
ROA % -53.89
FLKS's ROA % is ranked lower than
68% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. FLKS: -53.89 )
Ranked among companies with meaningful ROA % only.
FLKS' s ROA % Range Over the Past 10 Years
Min: -53.89  Med: -47.25 Max: -44.6
Current: -53.89
-53.89
-44.6
ROC (Joel Greenblatt) % -6713.59
FLKS's ROC (Joel Greenblatt) % is ranked lower than
84% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. FLKS: -6713.59 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
FLKS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12511.35  Med: -10507.92 Max: -6713.59
Current: -6713.59
-12511.35
-6713.59
GuruFocus has detected 1 Warning Sign with Flex Pharma Inc $FLKS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» FLKS's 30-Y Financials

Financials (Next Earnings Date: 2017-08-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

FLKS Guru Trades in Q2 2016

Jim Simons 14,400 sh (New)
PRIMECAP Management 790,911 sh (+24.61%)
Chuck Royce 2,200 sh (unchged)
» More
Q3 2016

FLKS Guru Trades in Q3 2016

Jim Simons 22,600 sh (+56.94%)
PRIMECAP Management 857,359 sh (+8.40%)
Chuck Royce 2,200 sh (unchged)
» More
Q4 2016

FLKS Guru Trades in Q4 2016

Chuck Royce 68,200 sh (+3000.00%)
PRIMECAP Management 1,082,600 sh (+26.27%)
Jim Simons Sold Out
» More
Q1 2017

FLKS Guru Trades in Q1 2017

Chuck Royce 242,200 sh (+255.13%)
PRIMECAP Management 1,472,800 sh (+36.04%)
» More
» Details

Insider Trades

Latest Guru Trades with FLKS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:NOVN, AMEX:RNN, NAS:AQB, OTCPK:PMCB, AMEX:SYN, NAS:CUR, NAS:CASI, NAS:APEN, TSXV:COB.U, NAS:ECYT, NAS:LPTX, AMEX:NBY, AMEX:ATNM, OTCPK:ORGS, NAS:EGLT, NAS:KALV, NAS:INFI, NAS:NVIV, NAS:ALDX, OTCPK:ANTB » details
Traded in other countries:FP1.Germany,
Headquarter Location:USA
Flex Pharma Inc is a biotechnology company. The Company is engaged in developing proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions.

Flex Pharma Inc is a biotechnology company incorporated in Delaware on February 26, 2014. The Company is engaged in developing proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. It is developing products to address muscle cramps and spasms by halting repetitive firing of the motor neurons. Its proprietary treatment stimulates transient receptor potential (TRP) channels located in the mouth, esophagus and stomach, activating receptors in the gastrointestinal tract. It has two reportable segments namely Consumer Operations and Drug Development. The Company faces competition from different sources, including pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Government authorities in the United States at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those it is developing. Any drug candidate that it develops must be approved by the FDA before it may be legally marketed in the United States and by the corresponding foreign regulatory agencies before it may be legally marketed in foreign countries. Dietary supplements, while generally not subject to premarket review, still must comply with numerous manufacturing, labeling and other regulations.

Top Ranked Articles about Flex Pharma Inc

Chuck Royce Continues to Buy These 10 Stocks Guru increased these holdings in the last 2 quarters
Chuck Royce (Trades, Portfolio) manages a portfolio composed of 1,116 stocks with a total value of $15.292 billion. In both the first quarter of 2017 and fourth-quarter 2016 the guru bought shares in the following stocks. Read more...
9 Stocks Primecap Management Continues to Buy Holdings the firm boosted during last 2 quarters
PRIMECAP Management (Trades, Portfolio) was founded in September 1983 in Pasadena, California, by Chairman and Chief Investment Officer Howard B. Schow, Vice Chairman Mitchell J. Milias and President Theo A. Kolokotrones. It manages Vanguard’s PRIMECAP Fund, Vanguard Capital Opportunity Fund and Vanguard PRIMECAP Core Fund. In both first-quarter 2017 and fourth-quarter 2016 the guru bought shares in the following stocks: Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.40
FLKS's PB Ratio is ranked higher than
88% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. FLKS: 1.40 )
Ranked among companies with meaningful PB Ratio only.
FLKS' s PB Ratio Range Over the Past 10 Years
Min: 1  Med: 1.49 Max: 2.95
Current: 1.4
1
2.95
PS Ratio 57.00
FLKS's PS Ratio is ranked lower than
77% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. FLKS: 57.00 )
Ranked among companies with meaningful PS Ratio only.
FLKS' s PS Ratio Range Over the Past 10 Years
Min: 40.53  Med: 90.73 Max: 1808.57
Current: 57
40.53
1808.57
EV-to-EBIT -0.65
FLKS's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. FLKS: -0.65 )
Ranked among companies with meaningful EV-to-EBIT only.
FLKS' s EV-to-EBIT Range Over the Past 10 Years
Min: -3.5  Med: -0.7 Max: -0.1
Current: -0.65
-3.5
-0.1
EV-to-EBITDA -0.65
FLKS's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. FLKS: -0.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
FLKS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.5  Med: -0.7 Max: -0.1
Current: -0.65
-3.5
-0.1
Current Ratio 17.04
FLKS's Current Ratio is ranked higher than
91% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. FLKS: 17.04 )
Ranked among companies with meaningful Current Ratio only.
FLKS' s Current Ratio Range Over the Past 10 Years
Min: 16.06  Med: 30.41 Max: 78.74
Current: 17.04
16.06
78.74
Quick Ratio 16.91
FLKS's Quick Ratio is ranked higher than
91% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. FLKS: 16.91 )
Ranked among companies with meaningful Quick Ratio only.
FLKS' s Quick Ratio Range Over the Past 10 Years
Min: 15.95  Med: 30.39 Max: 78.74
Current: 16.91
15.95
78.74
Days Inventory 199.04
FLKS's Days Inventory is ranked lower than
70% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. FLKS: 199.04 )
Ranked among companies with meaningful Days Inventory only.
FLKS' s Days Inventory Range Over the Past 10 Years
Min: 124.97  Med: 124.97 Max: 199.04
Current: 199.04
124.97
199.04
Days Sales Outstanding 5.53
FLKS's Days Sales Outstanding is ranked higher than
92% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. FLKS: 5.53 )
Ranked among companies with meaningful Days Sales Outstanding only.
FLKS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.33  Med: 4.33 Max: 5.53
Current: 5.53
4.33
5.53
Days Payable 548.50
FLKS's Days Payable is ranked higher than
95% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. FLKS: 548.50 )
Ranked among companies with meaningful Days Payable only.
FLKS' s Days Payable Range Over the Past 10 Years
Min: 548.5  Med: 656.23 Max: 656.23
Current: 548.5
548.5
656.23

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.49
FLKS's Price-to-Net-Cash is ranked higher than
94% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. FLKS: 1.49 )
Ranked among companies with meaningful Price-to-Net-Cash only.
FLKS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.18  Med: 2.33 Max: 3.23
Current: 1.49
1.18
3.23
Price-to-Net-Current-Asset-Value 1.43
FLKS's Price-to-Net-Current-Asset-Value is ranked higher than
94% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. FLKS: 1.43 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
FLKS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.13  Med: 2.24 Max: 3.2
Current: 1.43
1.13
3.2
Price-to-Tangible-Book 1.41
FLKS's Price-to-Tangible-Book is ranked higher than
91% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. FLKS: 1.41 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
FLKS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.12  Med: 2.22 Max: 3.19
Current: 1.41
1.12
3.19
Price-to-Median-PS-Value 0.63
FLKS's Price-to-Median-PS-Value is ranked higher than
78% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. FLKS: 0.63 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
FLKS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.5  Med: 1.95 Max: 15.95
Current: 0.63
0.5
15.95
Earnings Yield (Greenblatt) % -153.23
FLKS's Earnings Yield (Greenblatt) % is ranked lower than
97% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. FLKS: -153.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
FLKS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1141.7  Med: -140.4 Max: 4570.9
Current: -153.23
-1141.7
4570.9

More Statistics

Revenue (TTM) (Mil) $1.25
EPS (TTM) $ -2.32
Short Percentage of Float5.39%
52-Week Range $3.01 - 12.68
Shares Outstanding (Mil)17.97

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1 5 52
EPS ($) -2.73 -2.86 -3.36
EPS without NRI ($) -2.73 -2.86 -3.36
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for FLKS

Headlines

Articles On GuruFocus.com
Chuck Royce Continues to Buy These 10 Stocks May 16 2017 
9 Stocks Primecap Management Continues to Buy Apr 20 2017 
2 CEOs Make Big Buys of Their Companies’ Stocks May 25 2016 
CEO of Flex Pharma Buys Nearly 50,000 Shares Mar 28 2016 

More From Other Websites
FDA Grants Fast Track Designation to Flex Pharma’s FLX-787 for the Treatment of Severe Muscle... Jul 25 2017
Flex Pharma Announces Executive Leadership Transition Jun 05 2017
Flex Pharma’s Phase 2 Trial with FLX-787 in Charcot-Marie-Tooth Endorsed by the Inherited... Jun 02 2017
Flex Pharma Presenting at Upcoming Investor Conferences in June 2017 May 30 2017
Edited Transcript of FLKS earnings conference call or presentation 3-May-17 12:45pm GMT May 04 2017
Flex Pharma reports 1Q loss May 03 2017
Flex Pharma Reports First Quarter 2017 Financial Results May 03 2017
FDA Clears Flex Pharma's FLX-787 to Commence US Phase 2 Trial in ALS Under IND Apr 26 2017
Flex Pharma Presents Human Efficacy Data on FLX-787 at the American Academy of Neurology Annual... Apr 19 2017
Flex Pharma Names William K. McVicar, Ph.D. as President, Research & Development Apr 05 2017
Newly-Published Study Reinforces Efficacy Of HOTSHOT® In Preventing And Treating Muscle Cramps Mar 23 2017
Edited Transcript of FLKS earnings conference call or presentation 8-Mar-17 1:30pm GMT Mar 09 2017
Flex Pharma Reports Year End 2016 Financial Results Mar 08 2017
Flex Pharma to Report Fourth Quarter and Full Year 2016 Results on March 8, 2017 Mar 01 2017
Champion Triathlete Finds Solution For Struggle With Muscle Cramps Feb 15 2017
Flex Pharma to Present at the BIO CEO & Investor Conference Feb 07 2017
Flex Pharma Focuses on Phase 2 Clinical Programs in Severe Neurological Diseases Jan 24 2017
Champion Pro Football Fullback Goes On The Offense Against Game-Changing Cramps Dec 20 2016
Do Hedge Funds Love Vishay Precision Group Inc (VPG)? Dec 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}